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lin@mail.tsinghuAbstract Glypican-3 (GPC3) is reported as a great promising tumor marker for hepatocellular
carcinoma (HCC) diagnosis. Highly sensitive and accurate analysis of serum GPC3 (sGPC3), in
combination with or instead of traditional HCC marker alpha-fetoprotein (AFP), is essential for
early diagnosis of HCC. Biomaterial-functionalized magnetic particles have been utilized as solid
supports with good biological compatibility for sensitive immunoassay. Here, the magnetic
nanoparticles (MnPs) and magnetic microparticles (MmPs) with carboxyl groups were further
modiﬁed with streptavidin, and applied for the development of chemiluminescence enzyme
immunoassay (CLEIA). After comparing between MnPs- and MmPs-based CLEIA, MnPs-based
CLEIA was proved to be a better method with less assay time, greater sensitivity, better linearity
and longer chemiluminescence platform. MnPs-based CLEIA was applied for detection of sGPC3
in normal liver, hepatocirrhosis, secondary liver cancer and HCC serum samples. The results
indicated that sGPC3 was effective in diagnosis of HCC with high performance.
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Great progress has been made in clinical therapeutic strategies,
but patients with cancer are still undergoing poor effects of
therapy and high mortality rate [1–3]. Patients with cancer are
often asymptomatic in early stages [4–6] and consequently
are frequently diagnosed late. Prevention is one of the most
effective cancer-ﬁghting tools. Early diagnosis may allow for
timely prevention of malignancy and initiation of appropriate
therapies. Fortunately, the use of biomarkers in predicting
disease holds considerable promise and has played an important
role in early diagnosis [7]. Hepatocellular carcinoma (HCC) is
the third most common cancer because of cancer-related death.
Table 1 Optimization of the dilution ratios of HRP-
CLEIA based on MnPs for detection of HCC marker GPC3 167Alpha-fetoprotein (AFP), commonly regarded as a tumor marker
of HCC, has encountered challenges from other HCC markers
because of the low sensitivity of AFP. For example, glypican-3
(GPC3) [8], reported to be overexpressed in HCC, is considered
as an early tissue tumor marker for HCC [9–12]. Additionally, it
was reported that GPC3 was secreted into blood and could be
a serological tumor marker with higher sensitivity than AFP
[13–15]. In our previous work [16], competitive radioimmunoas-
say for detection of GPC3 had been developed, and tentative
clinical application showed that GPC3 presented higher sensitivity
and speciﬁcity than AFP in diagnosis of HCC.
In recent years, functionalized magnetic particles (MPs) [17]
have attracted tremendous interests in many biological appli-
cations, such as biomedicine [18], isolation of speciﬁc DNA
[19], mRNA subtraction [20,21] and manipulation cells [22].
Functionalized MPs are ﬁrst modiﬁed with amino or carboxyl
groups, and then proteins (e.g. antibodies/antigens) can be
covalently bond to MPs-carboxyl or MPs-amino [23,24].
However, biological activity of proteins might be affected by
steric hindrance and non-speciﬁc adsorption on the modiﬁed
MPs surface [25]. Therefore, some attempts have been made to
further modify MPs-carboxyl or MPs-amino with functional
ligands (e.g. streptavidin, second antibodies) [26,27] in order
to reduce the effect of steric hindrance and preserve the
bioactivity of proteins. Functionalized MPs, with the diameter
in the range from nanometers to micrometers, have been
applied for immunoassay with higher sensitivity [28–31] and
wider detection range [32]. However, to our knowledge, the
inﬂuence of the diameters of the particles and the role of MPs
in immunoassay have not been discussed in detail up to now.
Herein, we developed magnetic particles-based chemilumi-
nescence enzyme immunoassay (CLEIA) for detection of
serum GPC3 (sGPC3). Magnetic nanoparticles (MnPs) and
microparticles (MmPs) with carboxyl group were both mod-
iﬁed with streptavidin, and further used as solid phase for
coating GPC3 antibodies. MnPs-based CLEIA (MnPs-CLEIA)
was compared with MmPs-CLEIA in developing sensitive and
fast immunoassay. Finally, MnPs-CLEIA was applied to the
detection of sGPC3 in normal liver, hepatocirrhosis, secondary
liver cancer and HCC serum samples for evaluating its sensitivity
and speciﬁcity.GPC3 and B-GPC3 Ab through orthogonal test for the
development of MmPs-CLEIA and MnPs-CLEIA.
Dilution
ratios of
HRP-
GPC3
Dilution
ratios of
B-GPC3
Ab
MmPs-CLEIA
(%)
MnPs-CLEIA
(%)
RLUS1/
RLUS0
RLUS5/
RLUS0
RLUS1/
RLUS0
RLUS5/
RLUS0
1:1000 1:60 92 51 95 60
1:120 86 21 93 44
1:240 88 23 90 32
1:2000 1:60 95 19 90 29
1:120 85 17 88 27
1:240 91 24 85 24
1:4000 1:60 87 33 87 43
1:120 85 19 85 29
1:240 87 18 87 21
Detection conditions: 37 1C, 50 mL MPs (2.5 mg/mL), 50 mL
HRP-GPC3, 50 mL B-GPC3 antibody and 300 mL of chemi-
luminescence substrate.2. Experimental
2.1. Materials and apparatus
MnPs-carboxyl (100 nm in diameter, 10 mg/mL stock solu-
tion) and MmPs-carboxyl (2 mm in diameter, 10 mg/mL stock
solution) suspended in buffer solution were purchased from
Shanghai Allrun Nano Science & Technology Co., Ltd.
(Shanghai, China). Sheep immunized anti-human GPC3 anti-
body and horse radish peroxidase (HRP) labeled recombinant
human GPC3 were from R&D systems Inc. (Minneapolis,
USA). Streptavidin and biotin were from Vector Laboratories
Inc. (Burlingame, USA). Chemiluminescent substrate (luminol,
H2O2 and chemiluminescence enhancer) was obtained from
Monobind Inc. (America).
Blood samples were collected from Beijing Tumor Hospital
(Beijing, China). Approval was obtained from the Regional
Ethics Committee, and all subjects gave informed consent to
participate. HCC patients (30 males and 30 females) were atthe mean age of 50.7715.5 without any therapeutic approach.
Hepatocirrhosis patients (40 males and 20 females) were at the
mean age of 45.5720.5. Secondary liver cancer patients with
the mean age of 50.5712.5 were15 males and 15 females.
Normal liver serum samples were collected from 60 persons
(30 males and 30 females) of the mean age of 40.5710.5.
A universal luminometer (Hamatsu Photonics, Beijing, China)
with 60 test tubes (12-mm in diameter 60-mm in length) was
used for the chemiluminescence detection. A test tube rack
equipped with a samarium–cobalt magnet (4000 G) was used
for the magnetic separation. ZHWY-100 thermostatic culture
oscillator (Shanghai Zhicheng Analytical Instrument Manufac-
turing Co., Ltd., Shanghai, China) was used for incubation and
shaking procedures.
2.2. Preparation of biotin labeled polyclone anti-GPC3
antibody
Anti-GPC3 antibody (dissolved in 0.05 M carbonate buffer,
pH 8.0) was incubated with biotin-7-NHS (dissolved in
DMSO) at room temperature. After 2 h, the mixture was
dialyzed in carbonate buffer (0.05 M, pH 9.6) for 2 h to
discharge unbound biotin-7-NHS, and the repeated dialysis
treatment was carried out three times. Finally, biotin labeled
polyclonal anti-GPC3 antibody (B-GPC3 Abs) was stored in
borate buffer (pH 8.0) at 20 1C for further use.
2.3. Preparation of streptavidin modiﬁed magnetic particles
The protocol for the preparation of streptavidin modiﬁed
magnetic particles (SA-MPs) is brieﬂy summarized as follows.
The following operations were all performed at room tem-
perature. MPs-carboxyl was washed three times with 0.1 M
2-(N-morpholino) ethanesulfonic acid (MES, pH 5.0) buffer.
After that, MPs-carboxyl was activated by directly suspending
in MES buffer [containing 0.1 M 1-ethyl-3-(3-dimethylamino-
propyl) carbodiimide, EDC] with gentle shaking. After 10 min,
Q.-Y. Zhang et al.168the activated MPs-carboxyl was incubated with streptavidin
on a shaker for 2 h. Finally, streptavidin modiﬁed magnetic
particles (SA-MPs) were washed three times with 0.1 M
phosphate buffer solutions containing 0.05% (v/v) Tween-20
(PBST).
Anti-GPC3 antibodies coated MPs (anti-GPC3 Abs-MPs)
were simply prepared by incubating B-GPC3 Abs with SA-
MPs at 37 1C for 15 min. The prepared anti-GPC3 Abs-MPs
were suspended in 0.2 M borate buffer (pH 8.0) containing 2%
(w/v) BSA, 0.3% (v/v) Tween-20 and 0.1% (w/v) biologic
preservatives for further use.Figure 1 Inﬂuence of the concentration of magnetic particles (MPs) o
concentration of MnPs or MmPs; (B) optimization of the concentration o
experimental conditions: 37 1C, 50 mL HRP-GPC3 (1:2000), 100 mL of chem2.4. Immunoassay procedures of the chemiluminescence
enzyme immunoassay based on MnPs and MmPs
One-step competitive immunoassay was carried out by incu-
bating GPC3 calibrators (or serum samples), anti-GPC3 Abs-
MPs and HRP-GPC3 at 37 1C. After immunoreaction, the whole
mixture was washed four times with PBST buffer to remove
unbound immunoreagents. Luminescent substrate (100 mL) was
introduced into the immuno-complex, and incubated for 5 min at
room temperature. Finally, the emitted photons were measured as
relative luminescence unit (RLU).n chemiluminescence. (A) Comparison of RLUs with corresponding
f MnPs depending on chemiluminescence intensity and duration. The
iluminescent substrate, a serial concentration of anti-GPC3 Abs-MPs.
CLEIA based on MnPs for detection of HCC marker GPC3 1692.5. Data analysis
Standard curves were obtained by plotting the logit of RLU
against the logarithm of GPC3 concentration and ﬁtting to a
linear curve. Sensitivity of sGPC3 in diagnosis of HCC wasFigure 2 Inﬂuence of the MPs size on immunoreaction time. (A) Varia
time with MmPs. (B) Variation of RLUS1, RLUS0 and RLUS1/RLU
37 1C, 50 mL HRP-GPC3 (1:2000), 50 mL anti-GPC3 Abs-MPs, 100 mdeﬁned by true positive/(true positiveþfalse negative results). The
speciﬁcity was deﬁned by true negative/(true negativeþfalse
positive results). Fisher’s exact test and student’s t-test were used
for categorical variables analysis between groups. Signiﬁcant
difference was deﬁned as Po0.05.tion of RLUS1, RLUS0 and RLUS1/RLUS0 upon immunoreaction
S0 upon immunoreaction time with MnPs. Detection conditions:
L of chemiluminescent substrate.
Table 2 Comparison of analytical parameters.
Method Calibration curve Linear
range
(ng/
mL)
LOD
(ng/
mL)
Total
assay
time
(min)
MnPs-
CLEIA
logitY¼0.28190.2498
log X, r¼0.9973
0–2500 0.38 50
MmPs-
CLEIA
logitY¼1.69720.2618
log X, r¼0.9948
0–2500 1.05 100
RIA
[25]
logitY¼1.26320.6466
log X, r¼0.9965
0–500 0.5 150
Q.-Y. Zhang et al.1703. Results and discussion
3.1. Optimization of the concentration of B-GPC3 antibody
and HRP-GPC3
Concentrations of B-GPC3 Abs and HRP-GPC3, which
mainly determine the sensitivity and working range in an
immunoassay, were optimized according to inhibition ratios.
Inhibition ratios ranging from 85% to 15% were well
acceptable in competitive immunoassay for a good separation
and even distribution calibrator points in calibration curve.
Stock solutions of B-GPC3 Abs and HRP-GPC3 were step-
wise diluted to three titers, respectively. Orthogonal test with
two factors and three levels was carried out (Table 1). RLUs
decreased with the increasing concentration of HRP-GPC3
and B-GPC3 Abs. RLUS1/RLUS0 (86%) and RLUS5/RLUS0
(21%) in MnPs-CLEIA were acceptable at 1:1000 of HRP-
GPC3 and 1:120 of B-GPC3 Abs, respectively. RLUS1/RLUS0
(85%) and RLUS5/RLUS0 (21%) in MmPs-CLEIA were
acceptable at 1:2000 of HRP-GPC3 and 1:240 of B-GPC3
Abs, respectively. The results indicated that immunoreagents
might have a higher bioactivity with MnPs than with MmPs,
and the steric hindrance effect could be lower with MnPs than
with MmPs.
3.2. Optimization of the concentration of MPs
As shown in Fig. 1, the inﬂuence of the concentration of MPs
and MPs on chemiluminescence was investigated. RLUs were
decreased with the increasing concentration of MPs, but
RLUs by using MnPs were much higher than by MmPs with
the same concentration (Fig. 1A). Furthermore, the concen-
tration of MPs was extensively optimized. RLUs decreased
greatly after a short chemiluminescence platform (within
10 min) when too low concentration (0.125 mg/mL) of MnPs
was used (Fig. 1B). Considering an appropriate intensity of RLUs
attained, 0.25 mg/mL of MnPs was settled for MnPs-CLEIA.Figure 3 Chemiluminescence kinetics correspondinSimilar results were obtained for optimization of the concentra-
tion of MmPs. The difference was that 0.5 mg/mL of MmPs was
settled for MmPs-CLEIA. Obviously, the concentration of MnPs
was one fourth of MmPs by developing CLEIA, which might be
due to a larger effective area of MnPs than MmPs with the same
concentration of MPs.
3.3. Inﬂuence of the diameter of MPs on immunoreaction time
The inﬂuence of the diameter of MPs on immunoreaction time
was studied and the results are shown in Fig. 2. RLUS0 and
RLUS1 enhanced with immunoreaction time increasing. Inter-
estingly, the inhibition ratio of RLUS1/RLUS0 decreased with
immunoreaction time increasing, and reached 84% at 70 min
with MmPs and 85% at 40 min with MnPs. Immunoreaction
time of 70 min was consequently selected for further develop-
ing MmPs-CLEIA, and 40 min for MnPs-CLEIA. The less
immunoreaction time might be due to better reservation of
heterogeneous phase for MnPs holding in the immunoreaction
solution than MmPs, and increased collision reaction prob-
ability by MnPs compared with MmPs.g to the two kinds of MPs (MnPs and MmPs).
CLEIA based on MnPs for detection of HCC marker GPC3 1713.4. Inﬂuence of the diameter of MPs on chemiluminescence
kinetics
Furthermore, the inﬂuence of the diameter of MPs on
chemiluminescence kinetics was studied (Fig. 3). Although
RLUs with MnPs and MmPs both increased immediately with
time increasing, RLUs in MnPs-CLEIA were much higher
than in MmPs-CLEIA. In addition, RLUs in MnPs-CLEIAFigure 4 Calibration curve and linear dilution curve. (A) Calibration
intensity against the logarithm of concentration of calibrators; (B) lin
samples against dilution ratio.preserved a longer platform (from 3 to 40 min) than in
MmPs-CLEIA (from 9 to 20 min). The reasons might be
a higher bioactivity of HRP-GPC3 on MnPs surface than
on MmPs, and a better reservation of heterogeneous phase
for MnPs suspended in chemiluminescent substrate than
that for MmPs. Additionally, a smaller dosage of MnPs used
would give a lower absorbency of photo counts compared
with MmPs.curve was obtained by plotting the logistic of chemiluminescence
ear dilution curve was obtained by concentration of serial diluted
Q.-Y. Zhang et al.1723.5. Analytical parameters
On the basis of the above optimized conditions, we con-
structed MnPs-CLEIA. Analytical parameters were further
evaluated for detection of sGPC3 and compared with our
previous radioimmunoassay (RIA) [16]. As shown in Table 2,
MPs-CLEIA exhibited high performances than RIA in terms
of linear range, limit of detection (LOD) and total assay time.
This obviously resulted from greater sensitivity of counting
photo counts equipped with photomultiplier for chemilumi-
nescence detection than counting g rays in RIA. In addition,
MPs introduced to the immunoassay were another key factor
for improving sensitivity and accelerating immunoreaction.
3.6. Calibration curve and validity
Linearity of the calibration curve, displayed in Fig. 4A, was
obtained in the range of 2.0–2500 ng/mL (correlation coefﬁ-
cient r¼0.9973).
Validity was evaluated to study the effects of calibrator
matrix on the accuracy of the detection method. An HCC
serum sample was stepwise diluted (two-, four-, eight- and 16-
fold) by calibrator matrix, and GPC3 in these ﬁve samples was
determined by calibration curve. The relationship between
GPC3 concentration in the serial diluted HCC samples and
the dilution factors gave a high linearity (r¼0.9999) (Fig. 4B).
The results conﬁrmed that the calibrator matrix had a similar
biochemical characteristic to human serum for detection
of sGPC3.
3.7. Determination of the cut-off value of sGPC3 for HCC
diagnosis
GPC3 in serum samples collected from patients with normal
liver (NL) was evaluated with our proposed method. When we
adopted the cut-off points distinguishing normal liver andFigure 5 Correlation between results measured by the proposed Mn
between 0 and 300 ng/mL.other liver diseases at xþ 3SD (according to student’s t-test),
sGPC3 in about ninety-eight percents of the total samples was
below 21.10 ng/mL (xþ 3SD). So we set the cut-off point of
sGPC3 at 21.10 ng/mL (xþ 3SD) to distinguish normal liver
and benign liver diseases.3.8. Determination of sGPC3 in HCC, hepatocirrhosis and
secondary liver cancer serum samples
GPC3 in HCC serum samples was detected by MnPs-CLEIA
and compared with the results obtained by RIA (proposed
method of our previous work). As shown in Fig. 5, there was
a good agreement between the two methods in the range of
0–1400 ng/mL (r2¼0.9582), and also in the range of 0–300 ng/mL
(r2¼0.9203). Hence, the present proposed method was reliable
and could be used in the clinical diagnosis.
GPC3 levels in normal samples (NL), hepatocirrhosis and
HCC serum samples were compared by statistical method
(Fig. 6). As can be seen, sGPC3 in normal liver (3.8175.77 ng/
mL) was much lower than in HCC [(148.297215.76) ng/mL],
and the results showed a signiﬁcant difference between the two
groups (Po0.001). So using sGPC3 as an HCC tumor marker
and our proposed method, HCC could be well differentiated
from normal liver. Moreover, sGPC3 in hepatocirrhosis
[(18.69717.47) ng/mL] tended to be slightly elevated com-
pared with in normal liver, but still at a signiﬁcantly lower
level than in HCC samples. Moreover, sGPC3 in all of the
HCC samples was above 29.01 ng/mL (higher than the cut-off
value), and in 38.3% (23 case) of the hepatocirrhosis samples
was above the cut-off value. From the data we found that the
sensitivity of sGPC3 reached 100% and the speciﬁcity of
screening HCC from hepatocirrhosis reached 61.7%. There-
fore, we could conﬁrm that sGPC3 was an effective marker to
distinguish HCC from healthy individuals. What should be
mentioned is that sGPC3 in hepatocirrhosis patients might
elevate above cut-off value.Ps-CLEIA and RIA. Inset is the enlarged diagram with abscissa
Figure 6 Evaluation of sGPC3 in normal liver and HCC samples. Levels of sGPC3 in HCC, hepatocirrhosis and normal liver (NL) were
indicated by mean7SD (ng/mL); n is the number of samples. Inset is the enlarged diagram about the levels of sGPC3 in hepatocirrhosis
and normal liver.
CLEIA based on MnPs for detection of HCC marker GPC3 173Secondary liver cancer serum samples were also put into
consideration to evaluate speciﬁcity of GPC3. Among 30
secondary liver serum samples, sGPC3 in 90% of the total
samples had no elevation, and only in three samples had slight
elevation (26.36, 18.83 and 12.27 ng/mL, respectively). So our
proposed method with speciﬁcity of 90% was a useful tool for
screening HCC from secondary liver cancers.4. Conclusion
In this work, MnPs-based CLEIA with high performance was
successfully proposed for detection of the promising HCC
tumor marker sGPC3. MnPs-CLEIA exhibited smaller dosage
of MPs, shorter immunoassay time, longer chemiluminescence
platform and greater sensitivity than MmPs-CLEIA. The
bioactivity of anti-GPC3 antibody and HRP-GPC3 binding
to MnPs remained higher than binding to MmPs. Besides, by
successfully applying MnPs-CLEIA to detect sGPC3, the cut-
off value of sGPC3 in diagnosis of HCC was determined at
21.01 ng/mL. More importantly, our results conﬁrmed that
sGPC3 could well differentiate HCC patients from ones with
normal liver and secondary liver cancers. However, our results
suggest that the elevation of sGPC3 in hepatocirrhosis patients
may increase the difﬁculty in screening HCC from hepatocir-
rhosis, and should be paid attention to with further clinical
supervision.
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